# Clinical Trials Data KIT - Document 58

# Staging Candidiasis in ICU Patients

## Clinical Trial: https://clinicaltrials.gov/study/NCT01322698

"eligibilityCriteria": "Inclusion Criteria:\n\n\* Polynuclear neutrophils \\> 500/mm\\^3\n\* Hospitalized for \\> 48 hours in participating ICUs\n\nExclusion Criteria:\n\n\* Patients discharged from ICU in \\< 48h\n\* Patient diagnosed with invasive candidosis before entry to ICU\n\* Patient is taking an anti-fungal treatment\n\* polynuclear neutrophils \\< 500/mm\\^3\n\* patient transferred to another ICU\n\* patient included in the Abmidex protocole",  
 "healthyVolunteers": false,  
 "sex": "ALL",  
 "minimumAge": "18 Years",  
"stdAges": [  
"ADULT",  
"OLDER\_ADULT"  
],  
 "studyPopulation": "The target population includes patients in ICUs at the N\u00eemes and Montpellier University hospitals. This is a population of non-neutropenic patients (polynuclear neutrophils \\> 500/mm3) at risk of developing invasive candidiasis.",

Question:  
Based on the following clinical trial information, would a patient with a KIT gene mutation be eligible for the clinical trial?

Answer:  
Based on the provided clinical trial information, a patient with a KIT gene mutation is not specifically mentioned as either an inclusion or exclusion criteria. The eligibility criteria focus on the patient's medical condition related to polynuclear neutrophils counts, ICU stay duration, current antifungal treatments, and participation in another protocol. Since there is no mention of genetic criteria related to the KIT gene or any other genetic factor, having a KIT gene mutation would not directly affect eligibility based on the provided criteria.  
  
However, it's important to note that this conclusion is based on the data given. If the trial has additional unpublished criteria, or if certain gene mutations impact the medical status or treatment plan of the patient in a way that intersects with the given criteria (e.g., affecting polynuclear neutrophil count), it could be relevant. It is advisable to confirm with the trial coordinators or responsible medical professionals for the most accurate eligibility assessment.